0
0
- NSC.org
- NSC Shop
- Injury Facts
- Safety+Health Magazine
When setting up an opioid overdose response program, work with legal professionals to understand state and local laws and liability considerations. In the United States, every state has an Overdose Good Samaritan Law that provides legal protections to individuals who administer naloxone in good faith to someone experiencing an opioid overdose.
Learn more about applicable Overdose Good Samaritan state laws and employer liability considerations. In Canada, The Good Samaritan Drug Overdose Act provides some legal protection against personal drug possession charges for individuals who seek emergency help during an opioid poisoning. Learn more.
State laws are continuing to evolve regarding naloxone in the workplace. Review the information below to understand relevant naloxone in the workplace laws in your state.
Naloxone is an opioid overdose reversal medication commonly known as NARCAN. Learn more about naloxone. Build a program at your workplace, with this implementation guide.
Reference this fact sheet for guidance on overdose and OSHA recordability.
AB 1976 mandates the Occupational Safety and Health Standards Board to draft rulemaking proposals to revise regulations to require the inclusion of opioid antagonists in workplace first aid kits, with liability protections for those administering them, by Dec. 1, 2027. Learn more.
SB 395 facilitates the use of opioid antagonists for overdose fatality prevention by expanding access, authorizing possession and administration in schools, and mandating their availability in certain government buildings, while providing immunity to those acting in good faith. Learn more.
HB 5028 amends existing laws to allow state agencies to provide opioid antagonists at workplaces with trained employees, offering civil liability protection for their administration, effective July 1, 2025. Learn more.
SB 1099 requires naloxone to be co-located with Automated External Defibrillators (AEDs) in public buildings, funded by the Opioid Restitution Fund, with civil liability immunity for providers and users, and a deadline of Oct. 1, 2027, for full implementation. Learn more.
Executive Order 24-11 aims to make the state of Minnesota a recovery-friendly workplace, supporting employees affected by substance use disorder and promoting recovery through education, support and access to resources. While the order does not mandate naloxone in workplaces, it does include a directive to explore its availability in the feasibility of procuring and distributing opioid antagonist medication for state agencies. Learn more.
S3112A requires New York State public buildings to be equipped with opioid antagonists, with implementation guidelines and training to be developed by state commissioners. This was scheduled to take effect Dec. 17, 2025, one year after its enactment on Dec. 17, 2024. Learn more.
HB 342 mandates state agencies to possess naloxone, expands authorized personnel for its administration, and requires the Department of Health to develop a plan for the procurement and distribution of naloxone and other opioid antagonists to each state agency, and provide related informational resources. Learn more.
As of June 1, 2023, employers in Ontario must provide naloxone in the workplace if certain circumstances described in the Occupational Health and Safety Act apply. Learn more.
This information was updated in January 2026. The details shared above are for informational purposes only and do not constitute legal advice.
There are no items in your cart